Molecular Testing Has Limited Utility in the Surgical Evaluation of Bethesda III Thyroid Nodules

Volume: 268, Pages: 209 - 213
Published: Dec 1, 2021
Abstract
The Bethesda System for Reporting Thyroid Cytopathology has 6 diagnostic categories, each with an implied cancer risk of malignancy (ROM). Bethesda III, defined as atypia or follicular lesions of undetermined significance (AUS/FLUS) on fine needle aspiration (FNA), has an indeterminate ROM. This study investigates the utility of Afirma Gene Expression Classifier (GEC) and Thyroid Sequencing (ThyroSeq) molecular testing to predict malignancy in...
Paper Details
Title
Molecular Testing Has Limited Utility in the Surgical Evaluation of Bethesda III Thyroid Nodules
Published Date
Dec 1, 2021
Volume
268
Pages
209 - 213
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.